Condition: Myelodysplastic Syndromes · Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts · Mixed Myelodysplastic/Myeloproliferative Disease · Sponsor: Karolinska University Hospital
The goal of this interventional study is to evaluate if pre-emptive intervention using Azacitidine and / or donor lymphocytes or tapering of immune suppression in measurable residual disease (MRD) positive subjects can prevent clinical relapse. Participants will undergo MRD surveillance and be subjected to intervention in case of MRD positivity. Results will be compared with NMDSG14B, part one, in which MRD was analyzed in included patients without recieving intervention.
This description comes directly from the study's public registry record.
Magnus Tobiasson, PhD · 0046858580000 · magnus.tobiasson@ki.se
Always discuss trial participation with your own doctor first.
| Department of Hematology, Karolinska University Hospital | Stockholm, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05788679